Travers (original) (raw)
Latest News for: travers
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Norfolk Daily News 12 Jun 2026
Travere Therapeutics, Inc. (Nasdaq. TVTX) today announced that on June 10, 2026, the Compensation Committee of its ... .
Notice of Proposed Sale of Securities (Form 144) (Travere Therapeutics Inc)
Public Technologies 12 Jun 2026
). The text version of this document is not available ... Travere Therapeutics Inc.
Boom Boom: Pat Travers to put out the lights in Hobart
The Indiana Times 11 Jun 2026
Rock and blues guitar legend Pat Travers will perform Friday at Hobart Art Theater, with a free pre-show meet-and-greet at The Record Bin ... .
HORSE RACING: G2 Jim Dandy, Travers possible for Renegade; allowance likely next spot for Powershift
The Oneida Daily Dispatch 09 Jun 2026
SARATOGA SPRINGS, N.Y.
The ACT wants 26,000 new homes built in the next five years. Here's what that ...
Australian Broadcasting Corporation 09 Jun 2026
The ACT government describes its land release and housing supply program as "ambitious" but "achievable". So what are these 26,000 homes going to look like, and where are they going to be built? ... .
Ahead of Basel, London Gallery Weekend Put a Defiant, Energized City Scene on Display
New York Observer 09 Jun 2026
Just around the corner, Union Pacific was showing Georgia May Travers Cooks’s nostalgic paintings, contextualized by a rural, fairy-tale-like narrative, emphasized by a country-home framework built by ...
Golden Tempo Headed to Jim Dandy, Travers at Saratoga
Bloodhorse 07 Jun 2026
The year may be halfway over, but Golden Tempo seems a lot more than halfway to being crowned the champion 3-year-old male ... .
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class ...
Antara News 05 Jun 2026
Hong Kong (ANTARA/ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc ... Travere will ...
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the ...
Enid News & Eagle 04 Jun 2026
SAN DIEGO--(BUSINESS WIRE)--Jun 4, 2026-- ... .
Charter school leaders raise equity concerns over DC school funding
Wtop 04 Jun 2026
D.C. public charter school leaders and advocates are raising concerns over what they call a funding gap in the mayor’s proposed education budget, even as overall funding for public schools is set to increase in fiscal 2027 ... Related stories.
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class ...
Rutland Herald 02 Jun 2026
SAN DIEGO--(BUSINESS WIRE)--Jun 2, 2026-- ....
Material Agreement (Form 8-K) (Travere Therapeutics Inc)
Public Technologies 02 Jun 2026
). Item 1.01 Entry into a Material Definitive Agreement. On June 1, 2026, Travere Therapeutics, Inc ... Ltd ... Everest is obligated to make such payment following its receipt of the upfront payment from the Company described below ... Travere Therapeutics Inc.
North Canberra Hospital to cost $1.5b, will be ready in 2031
Australian Broadcasting Corporation 02 Jun 2026
The ACT government unveils details of the new North Canberra Hospital as part of its latest budget, with the total cost of the project now expected to be $1.5 billion ... .
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. ...
Business Wire 28 May 2026
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq ... Patent Application No.
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy (Travere Therapeutics Inc)
Public Technologies 27 May 2026
SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc ... About Travere Therapeutics. At Travere Therapeutics, we are in rare for life ... For more information, visit travere.com ... 888-969-7879 ir@travere.com ... 888-969-7879 mediarelations@travere.com.